人民财讯1月6日电，据迪安诊断（300244）消息，近日，广西壮族自治区科技厅正式公布"2026年第一 批广西科技计划拟立项项目名单"，迪安诊断子公司广西迪安与南宁市第四人民医院、广东省人民医院 联合申报的"赋能"行动计划重点研发课题《磁性荧光免疫层析检测平台用于百日咳等呼吸道感染快速诊 断的研究》成功获批。项目团队将联合多家科研机构，围绕磁性荧光免疫层析检测技术在百日咳等呼吸 道感染快速诊断中的应用，开展技术攻关，致力于突破现有技术瓶颈，构建更快速、更精准、易推广的 检测方案，助力实现临床早期精准诊断与防控。 ...

证券日报网讯 1月5日，迪安诊断发布公告称，公司于2025年12月31日召开职工代表大会，经与会职工 代表表决，选举刘洋女士担任公司第五届董事会职工代表董事，任期自职工代表大会选举通过之日起至 第五届董事会届满之日（2026年11月3日）止。 （文章来源：证券日报） ...

证券日报网讯 1月5日，迪安诊断发布公告称，控股股东陈海斌将所持1736万股公司股份质押续期至 2026年6月30日，占其持股10.56%，对应公司总股本2.78%，质权人为招商证券股份有限公司。 （文章来源：证券日报） ...

证券代码：300244 证券简称：迪安诊断 公告编号：2026-001 迪安诊断技术集团股份有限公司 关于控股股东部分股份质押续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于近日接到公司控股 股东陈海斌先生通知，获悉其将持有的公司部分股份办理了质押续期，相关手续 已办理完毕。具体事项如下： 一、股东股份本次质押续期的基本情况 本次股份质押为控股股东陈海斌先生对前期股份质押的续期，不涉及新增融 资，具体情况如下： | 股东 | 是否为控 股股东或 | 本次质 | 占其所 | 占公司 | 是否 | 是否为 | 质押 | 质押 | 续期 后质 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 第一大股 | 押数量 | 持股份 | 总股本 | 为限 | 补充质 | 起始 | 到期 | | 质权人 | 质押 用途 | | | 东及其一 | （万股） | 比例 | 比例 | 售股 | 押 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2026-002 迪安诊断技术集团股份有限公司 关于选举第五届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会 2026 年 1 月 5 日 附件：公司第五届董事会职工代表董事简历 刘洋，女，1981 年出生，中国国籍，无境外永久居留权。2004 年 7 月加入公司，历任 ICL 质量管理部总监、ICL 质量管理部总经理、实验室 管理中心兼交付中心常务副总经理等职务；2020 年 9 月至 2023 年 11 月 曾任公司职工代表监事。 截至本公告披露日，刘洋女士持有公司 13,400 股股份，与公司控股 股东、实际控制人、持股 5%以上股份的股东及公司董事、高级管理人员 不存在关联关系。未受到中国证监会及其他有关部门的处罚和证券交易所 任何惩戒，不存在《公司法》和《公司章程》规定的不得担任公司职工代 表董事的情形，亦不是失信被执行人，符合有关法律、行政法规、部门规 章及规范性文件等要求的任职资格。 迪安诊断技术集团股份有限公司（以下简称"公司"）于2025年12月31日召开 ...

北京德恒（杭州）律师事务所 关于迪安诊断技术集团股份有限公司 2025年第一次临时股东大会的 法律意见书 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 邮编：310016 电话：(+86)0571-86508080 传真：(+86)0571-87357755 北京德恒（杭州）律师事务所 关于迪安诊断技术集团股份有限公司 2025年第一次临时股东大会的法律意见书 北京德恒（杭州）律师事务所 德恒【杭】书（2025）第 12073 号 致：迪安诊断技术集团股份有限公司 迪安诊断技术集团股份有限公司（下称"公司"）2025 年第一次临时股东 大会（下称"本次股东大会"）于 2025 年 12 月 31 日（星期三）14:30 在杭州市 西湖区三墩镇金蓬街 329 号召开。北京德恒（杭州）律师事务所（下称"本所"） 受公司委托，指派本所律师出席本次股东大会。根据《中华人民共和国公司法》 （下称"《公司法》"）《上市公司股东大会规则》（下称"《股东大会规则》"） 等相关法律、法规、规范性文件以及《迪安诊断技术集团股份有限公司章程》（下 称"《公司章程》"）和《迪安诊断技术集团股份有限公司股东大会议事规 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2025-044 迪安诊断技术集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 （1）现场会议时间：2025 年 12 月 31 日（星期三）14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 12 月 31 日 9:15-9:25、9:30-11:30、13:00-15:00；通过深圳证券交 易所互联网投票系统的具体时间为：2025 年 12 月 31 日 9:15-15:00。 2、会议召开地点：杭州市西湖区三墩镇金蓬街 329 号。 3、会议召开方式：本次股东大会以现场投票与网络投票相结合的方式召开。 4、会议召集人：公司董事会。 5、会议主持人：陈海斌先生。 6、会议出席情况： 二、议案审议情况 本次股东大会采取现场记名投票与网络投票表决相结合的方式 ...

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

Core Viewpoint - The Biotech Economy Index (970038) closed at 2120.29 points, down 0.12%, with a trading volume of 13.62 billion yuan and a turnover rate of 1.11% [1] Group 1: Index Performance - On the day, 16 stocks in the Biotech Economy Index rose, with Deep Technology leading at a 2.83% increase, while 30 stocks fell, with Dean Diagnostics leading the decline at 2.96% [1] - The net outflow of main funds from the Biotech Economy Index stocks totaled 640 million yuan, while retail investors saw a net inflow of 454 million yuan [1] Group 2: Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (sz300760) with a weight of 12.66% and a market cap of 242.125 billion yuan [1] - Shizhu Aoshi (sz002252) with a weight of 4.95% and a market cap of 42.549 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 4.56% and a market cap of 38.832 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.17% and a market cap of 51.585 billion yuan [1] - Taige Pharmaceutical (sz300347) with a weight of 4.10% and a market cap of 44.119 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.87% and a market cap of 270.899 billion yuan [1] - Deep Technology (sz000021) with a weight of 3.86% and a market cap of 38.318 billion yuan [1] - Jiao Yue Medical (sz002223) with a weight of 3.22% and a market cap of 37.854 billion yuan [1] - Aimeike (sz300896) with a weight of 3.04% and a market cap of 43.694 billion yuan [1] - Watson Bio (sz300142) with a weight of 3.00% and a market cap of 17.833 billion yuan [1] Group 3: Fund Flow Details - The fund flow details indicate that Deep Technology had a main fund net inflow of 151 million yuan, while retail investors had a net outflow of 91.497 million yuan [2] - Kanglong Chemical experienced a main fund net inflow of 17.121 million yuan, with retail investors seeing a net inflow of 1.917 million yuan [2] - The Biotech Economy Index constituents underwent adjustments, adding 9 stocks and removing 9 stocks [2][3]